Phoenix-backed Sygnature acquires XenoGesis

Sygnature has doubled its drug metabolism and pharmacokinetics (DMPK) capabilities and expertise with the acquisition of XenoGesis, according to a statement. The acquirer's own DMPK department was established in 2015.

The two companies have had a working relationship for years and the firm's management team will stay on with the company following the transaction.

Phoenix acquired Sygnature in September 2017, drawing equity from its 2016 fund, which closed on £415m in July 2017. The GP typically invests in companies with enterprise values of £30-150m. However, according to filings at Companies House, loan notes totalling approximately £41.5m were structured in the deal, alongside ordinary shares worth almost £1m.

Previously, Sygnature has acquired in-vivo pharmacology clinical research organisations RenaSci and Alderley Oncology.

Company
XenoGesis was founded in 2011 by Richard Weaver, and specialises in pre-clinical DMPK, quantitative bioanalysis, in-vitro pharmacology and expert interpretation for clinical trials. It is based in Nottingham.

People
Sygnature – Simon Hirst (CEO, founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• UK / Ireland
• Healthcare
• healthcare
• Build-up
• Buy-and-build
• United Kingdom
• Phoenix Equity Partners